Synthetic Minds | Five Tech Giants Just Split Drug Discovery

The Synthetic Minds newsletter offers short daily insights to get you thinking. If you enjoy it, please forward. If you need more insights, subscribe to Futurwise and get 25% off for the first three months!

I have just launched the Intelligence Age Scorecard! It will help you understand how ready your organization is for the Intelligence Age. Take it today, it takes 15 minutes and you are prepared for what is to come.

Today’s topic: Health & Longevity

Five Tech Giants Just Split Drug Discovery in Five

Two weeks ago, OpenAI shipped GPT-Rosalind, its first life sciences model, and signed Novo Nordisk as its launch partner. Amazon released Bio Discovery, an agentic platform with 40-plus biological foundation models and integrated wet-lab partners.

That was the opening move. Within days, every major technology company had staked a position.

GPT-Rosalind posted the top BixBench score (0.751), beating GPT-5.4 and Gemini 3.1 Pro. Biotech service stocks fell three to five percent. Anthropic appointed Novartis CEO Vas Narasimhan to its board and acquired Coefficient Bio for 400 million dollars.

Amazon's platform let Memorial Sloan Kettering generate 300,000 antibody candidates and route the top 100,000 to Twist Bioscience for synthesis — compressing a year into weeks. Google's Isomorphic Labs built the world's best AI-designed drug lab, and Lilly built its own AI factory: 1,016 NVIDIA Blackwell GPUs.

That is the signal.

Five architectures, five owners, zero interoperability.

OpenAI sells the model. Anthropic buys the expertise. Amazon sells the workflow. Isomorphic keeps the engine and designs the drugs itself. Lilly builds its own factory.

Here is what it means. The platform you choose determines who owns the intelligence beneath your science. None of these architectures is compatible with the others. Switch later and you leave the data, the fine-tuning, and the institutional knowledge behind.

That is not a technology decision. It is a governance decision. And right now, no one is writing the rules.

'Synthetic Minds' continues to reflect the synthetic forces reshaping our world. Quick, curated insights to feed your quest for a better understanding of our evolving synthetic future, powered by Futurwise:

1. Imagine a world where surfaces can kill viruses on contact, reducing the spread of disease in shared spaces. Researchers at RMIT University have made this vision a reality with their breakthrough nanotextured material. (New Atlas)

2. Evolving AI (eAI) systems that can undergo Darwinian evolution are projected to appear before artificial general intelligence, raising significant control and alignment challenges. (TechXplore)

3. The rise of AI has brought about a new era of security challenges, as AI-powered attacks become increasingly sophisticated and difficult to detect, which is especially relevant for the healthcare sector. (SiliconAngle

4. Taylor Swift has filed three trademark applications to protect her image and voice amid rising AI deepfake threats. The filings cover a famous pink‑guitar photo from her Eras tour and two sound marks. (Wired)

5. AI chatbots are increasingly engineered to sound warm and empathetic, yet a recent Oxford study reveals that this cosmetic friendliness can erode factual accuracy and amplify misinformation, especially when users feel vulnerable. (Neuroscience)

If you are interested in more insights, grab my latest, award-winning, book Now What? How to Ride the Tsunami of Change and learn how to embrace a mindset that can deal with exponential change.

If this newsletter was forwarded to you, you can sign up here.

Thank you.
Mark